The Relationship of the Structure of Antipsychotic Prescriptions with Socio-Demographic and Clinical-Dynamic Indicators in Patients with Paranoid Schizophrenia
Open Access
- 22 December 2025
- journal article
- Published by Medical Informational Agency Publishers in Psychiatry (Moscow) (Psikhiatriya)
- Vol. 23 (5) , 6-16
Abstract
Background: it is well known that improving clinical guidelines should take into account the results of studies conducted in real-world clinical practice. Data of the prescription patterns and dosages of antipsychotic medications in patients with schizophrenia of varying disease duration are in the area of special interest. The aim was to study the relationship between the prescription patterns of antipsychotics and the socio-demographic, clinical and dynamic characteristics, quality of life indicators, and social functioning of patients with paranoid schizophrenia. Patients and Methods: the study included 208 inpatients with paranoid schizophrenia (total sample; mean age — 30.21 ± 6.84 years, males — 58.65% ( n = 122)). The structure of antipsychotic prescriptions was analyzed based on medical records from 2018 to 2024. For all medications, the standard daily dose was determined using the Defined Daily Dose (WHO) methodology. Socio-demographic, clinical and dynamic characteristics were assessed, along with PANSS, BACS, PSP, and WHOQOL-BREF scale scores. Results: a total of 16 antipsychotic drugs were identified in the prescription structure. Two patient groups were identified in the principal component space. Group 1 included patients with a significant (> 60%) predominance of risperidone and olanzapine prescriptions ( n = 136). Group 2 made up patients with a comparable predominance of haloperidol and clozapine prescriptions ( n = 72). Group 1 included 94 (69.1%) patients experiencing their first psychotic episode, whereas Group 2 included 50 (69.4%) chronic patients. Group 1 had significantly lower disease duration, number of hospitalizations ( p < 0.001), number of disabilities ( p = 0.003); significantly higher mean duration of outpatient treatment ( p < 0.001), higher scores on the BACS subtests “verbal learning” ( p = 0.009) and “working memory” ( p = 0.049). Conclusion: risperidone, olanzapine, and other second-generation antipsychotics are significantly more frequently prescribed in real-world clinical practice to patients with shorter disease duration and relatively preserved cognitive functions. In contrast, haloperidol and clozapine predominate in the prescriptions of chronic patients.Keywords
This publication has 28 references indexed in Scilit:
- Antipsychotic Drugs and Cognitive FunctionJAMA Psychiatry, 2025
- 20‐year trajectories of positive and negative symptoms after the first psychotic episode in patients with schizophrenia spectrum disorder: results from the OPUS studyWorld Psychiatry, 2023
- Clinical determinants, patterns and outcomes of antipsychotic medication prescribing in the treatment of schizophrenia and schizoaffective disorder: A naturalistic cohort studyJournal of Psychiatric Research, 2022
- Evolution of antipsychotic-induced extrapyramidal symptoms in patients with schizophrenia in the real-life: A 4-year follow-up naturalistic studySchizophrenia Research, 2022
- Comparative efficacy and tolerability of 32 oral and long-acting injectable antipsychotics for the maintenance treatment of adults with schizophrenia: a systematic review and network meta-analysisThe Lancet, 2022
- Sustained symptomatic remission in schizophrenia: Course and predictors from a two-year prospective studySchizophrenia Research, 2022
- Psychopharmacological Treatment of Schizophrenia Over Time in 30 908 Inpatients: Data From the AMSP StudyInternational Journal of Neuropsychopharmacology, 2019
- The Brief Assessment of Cognition in Schizophrenia: reliability, sensitivity, and comparison with a standard neurocognitive batterySchizophrenia Research, 2004
- The Nonparametric Behrens-Fisher Problem: Asymptotic Theory and a Small-Sample ApproximationBiometrical Journal, 2000
- The Positive and Negative Syndrome Scale (PANSS) for SchizophreniaSchizophrenia Bulletin, 1987